GelrinC
-
Biologics
Patients With Knee Cartilage Defects Recruited For Chicago Study Using Cutting-Edge Procedure To Help Regrow Cartilage
CHICAGO, Nov. 8, 2018 /PRNewswire/ — Active people who are struggling with knee pain or knee cartilage abnormalities may benefit from a Rush University Medical…
Read More » -
Biologics
Regentis Biomaterials Expands SAGE Clinical Trial of GelrinC™ for Knee Pain
October 23, 2018 PRINCETON, N.J. & OR AKIVA, Israel–(BUSINESS WIRE)–Regentis Biomaterials today announced it has expanded the SAGE clinical trial of GelrinC™…
Read More » -
Biologics
Regentis Biomaterials Performs the First Cases in GelrinC Pivotal Study
PRINCETON, New Jersey and OR AKIVA, Israel, November 28, 2017 /PRNewswire/ — Regentis Biomaterials announced today the start of its Phase III pivotal clinical trial…
Read More » -
Biologics
Regentis Biomaterials Receives European CE Mark Approval for GelrinC
OR AKIVA, Israel and PRINCETON, New Jersey, August 28, 2017 /PRNewswire/ — Regentis Biomaterials Ltd., a privately held company developing proprietary hydrogels for tissue regeneration,…
Read More » -
Hospitals
Regentis Receives IDE Approval for Pivotal GelrinC Clinical Trial
Princeton, NJ and Or Akiva, Israel, September 26 — Regentis Biomaterials, a developer of hydrogels for tissue regeneration, announced it…
Read More »